Delisting risk
Senti Biosciences
Gene-circuit developer for programmable cell and gene therapies.
$0.3946
After-hours close+0.02 (+6.08%)
At close$0.3720(−1.46%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 0.81%253.8K sharesInsiders 2.40%747.4K sharesOther 96.79%30.14M shares
Shares outstanding 31.14M · Float 12.28M · 39.4% free float
Institutions13F, as of Sep 30, 2025
1 holder · 253.8K shares · 0 new positions · 0 increased · 0 reduced · 0 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| 8VC GP I, LLC | 253.8K | 0.81% | 0 | Nov 12, 2025 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| CPIF II-7 Limitedincl. Celadon Partners SPV 24, Celadon Partners, LLC | 54.60% | 25.75M | 13D | Jul 16, 2026 ↗ |
| Bayer HealthCare LLCincl. Priyal Patel, Sebastian Guth +1 more | 17.82% | 6.14M | 13D | Apr 16, 2026 ↗ |
| New Enterprise Associates 15, L.P.incl. Mohamad H. Makhzoumi, NEA Partners 15, L.P. +4 more | 12.10% | 3.78M | 13D | Mar 31, 2026 ↗ |
| Nantahala Capital Management, LLC | 8.12% | 2.22M | 13G | May 15, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Celadon Partners SPV 24 | 10 percent owner | 9.78M | 31.39% | Mar 14, 2025 |
| New Enterprise Associates 15, L.P. | 10 percent owner | 3.78M | 12.12% | Mar 12, 2025 |
| Bayer Healthcare LLC | 10 percent owner | 2.81M | 9.02% | Mar 12, 2025 |
| Timothy K. Lu | director, officer: CEO | 639.6K | 2.05% | Mar 11, 2026 |
| Kanya Rajangam | officer: Pres. & Chief Med. & Dev. Off. | 107.8K | 0.35% | Mar 11, 2026 |
4 ten-percent owners hold 16.43M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 12 people have not refiled in the last 18 months (430.6K shares), so they are not in the figure above
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.